Investing.com - Cerevel Therapeutics Holdings (NASDAQ: CERE) reported second quarter EPS of $-0.63, $0.04 better than the analyst estimate of $-0.67. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Cerevel Therapeutics Holdings's stock price closed at $30.65. It is down -5.72% in the last 3 months and down -7.64% in the last 12 months.
Cerevel Therapeutics Holdings saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Cerevel Therapeutics Holdings's stock price’s past reactions to earnings here.
According to InvestingPro, Cerevel Therapeutics Holdings's Financial Health score is "fair performance".
Check out Cerevel Therapeutics Holdings's recent earnings performance, and Cerevel Therapeutics Holdings's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar